Last reviewed 2026-06-03 · How we verify

Synchrodyn (ALSACTIDE)

Phase 2 active Recombinant protein ✓ Verified Jun 2026

Synchrodyn (generic name: ALSACTIDE) is a alsactide drug. It is currently in Phase 2 development.

Synchrodyn works by binding to specific receptors or enzymes to modulate their activity and produce a therapeutic effect.

Synchrodyn is a protein modality. It is also known by the synonyms ALSACTIDA, ALSACTIDE, HOE-433, and ALSACTIDE.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ALSACTIDE
Drug class	alsactide
Modality	Recombinant protein
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine Synchrodyn as a key that fits into a lock on a cell's surface. When it binds, it can either turn the lock to open up a new pathway for helpful molecules to enter the cell or block the lock to prevent harmful molecules from entering. This can help to restore balance and promote healing in the body.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Synchrodyn CI brief — competitive landscape report
Synchrodyn updates RSS · CI watch RSS

Frequently asked questions about Synchrodyn

What is Synchrodyn?

Synchrodyn (ALSACTIDE) is a alsactide drug.

How does Synchrodyn work?

Synchrodyn works by binding to specific receptors or enzymes to modulate their activity and produce a therapeutic effect.

What is the generic name of Synchrodyn?

ALSACTIDE is the generic (nonproprietary) name of Synchrodyn.

What drug class is Synchrodyn in?

Synchrodyn belongs to the alsactide class. See all alsactide drugs at /class/alsactide.

What development phase is Synchrodyn in?

Synchrodyn is in Phase 2.

Drug class: All alsactide drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing